Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Receives Orphan Drug Designation for Satralizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder from the Ministry of Health, Labour and Welfare

share with twitter share with LinkedIn share with facebook
09/16/2019 | 09:54am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that satralizumab (development code: SA237), a pH-dependent binding humanized IL-6 receptor monoclonal antibody under development received orphan drug designation by the Ministry of Health, Labour and Welfare (MHLW) for neuromyelitis optica (NMO) and neuromyelitis optica spectrum disorder (NMOSD).

This designation is based on two global phase III clinical studies (SakuraStar Study and SAkuraSky Study), which showed efficacy and safety either in monotherapy or add-on therapy to baseline treatment.

'NMOSD including NMO, one of the intractable diseases designated by MHLW, are autoimmune diseases with limited treatment options and high unmet medical needs. With our proprietary antibody recycling technologies, satralizumab is designed to effectively inhibit IL-6 signal transduction that is deeply related to the pathology of the diseases,' said Dr. Yasushi Ito, Chugai's Executive Vice President, Co-Head of Project & Lifecycle Management Unit. 'We are working on the regulatory filings for satralizumab with confirmed effectiveness both in monotherapy and add-on to baseline treatment to deliver it to patients as soon as possible.'

About satralizumab

Satralizumab, created by Chugai, is a pH-dependent binding humanized IL-6 receptor monoclonal antibody, applying its recycling antibody technology. The drug is expected to suppress relapse of NMOSD by inhibiting IL-6 transduction which is deeply related to the pathology. In two global phase III clinical studies in NMOSD patients, the primary endpoint was achieved with satralizumab either as an add-on therapy to baseline treatment (NCT02028884) or as monotherapy (NCT02073279). Satralizumab is designated as an orphan drug in the U.S. and Europe. In addition, it has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration in December 2018.

About neuromyelitis optica spectrum disorder (NMOSD)

NMOSD is a rare, lifelong, and debilitating autoimmune disease of the central nervous system (CNS) characterized by inflammatory lesions in the optic nerves and spinal cord. Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability. Symptoms may include visual impairment, motor disability, and loss of quality of life. In some cases, attacks of NMOSD result in death. NMOSD is commonly associated with pathogenic antibodies (AQP4-IgG) that target and damage a specific central nervous cell type, called astrocytes resulting in inflammatory lesions of the optic nerve(s), spinal cord and brain. AQP4-IgG are detectable in the blood serum of around two-thirds of NMOSD patients 1-4. The inflammatory cytokine IL-6 is now emerging as an important factor in NMOSD pathogenesis 5-8.

Diagnostic criteria introduced in 2006 for NMO were characterized by inflammation of the optic nerve (optic neuritis) and the spinal cord (myelitis). These were revised in 2007 with the definition of NMOSD, proposed for diseases with either optic neuritis or myelitis. In 2015, the definition of NMOSD further revised to include a broader spectrum of disease. The diagnostic term NMOSD is now widely used 9.

About orphan drugs

Based on Pharmaceuticals and Medical Devices Law, orphan drugs are designated by the Minister of Health, Labour and Welfare and granted priority review. The designation criteria are as follows: The number of patients who may use the drug is less than 50,000 in Japan; The drug is indicated for the treatment of serious diseases and there is a significant medical value such as no alternative appropriate drug or treatment, or high efficacy or safety expected compared to existing products; there is a theoretical rationale for using the product for the targeted disease and the development plan is reasonable.

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2019 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD. -0.23% 5520 End-of-day quote.64.29%
ROCHE HOLDING AG 0.49% 329.8 Delayed Quote.6.70%
share with twitter share with LinkedIn share with facebook
Latest news on CHUGAI PHARMACEUTICAL CO.,
08:55aCHUGAI PHARMACEUTICAL : Results of Maruho's Phase III Study with Chugai's Nemoli..
AQ
06/30CHUGAI PHARMACEUTICAL : Enspryng Subcutaneous Injection 120 mg Syringe Approved ..
AQ
06/30CHUGAI PHARMACEUTICAL : Files a New Drug Application for Polatuzumab Vedotin for..
AQ
06/29ROCHE : ENSPRYNG®️ (satralizumab) approved in Japan for adults and childr..
AQ
06/29CHUGAI PHARMACEUTICAL CO., LTD. : SPLIT: 3 of 1
FA
06/29CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for interim dividend
FA
06/22CHUGAI PHARMACEUTICAL : - Phase III IPATential150 Study Evaluating Ipatasertib i..
AQ
06/19CHUGAI PHARMACEUTICAL : Tecentriq in combination with chemotherapy meets primary..
AQ
06/08Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as ..
AQ
06/01CHUGAI PHARMACEUTICAL : Updated Data of Overall Survival and Safety from the ALE..
AQ
More news
Financials
Sales 2020 755 B 7 039 M 7 039 M
Net income 2020 217 B 2 025 M 2 025 M
Net cash 2020 330 B 3 074 M 3 074 M
P/E ratio 2020 45,7x
Yield 2020 0,88%
Capitalization 9 068 B 84 554 M 84 518 M
EV / Sales 2019
EV / Sales 2020 11,6x
Nbr of Employees 7 394
Free-Float 37,7%
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO.,
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 4 369,50 JPY
Last Close Price 5 520,00 JPY
Spread / Highest target 26,8%
Spread / Average Target -20,8%
Spread / Lowest Target -78,9%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Executive Officer & GM-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.64.29%84 567
JOHNSON & JOHNSON-2.07%377 458
ROCHE HOLDING AG5.27%299 642
MERCK & CO., INC.-14.33%196 678
NOVARTIS AG-10.23%193 644
PFIZER, INC.-13.86%187 476